Sarepta Therapeutics is expected to report Q3 2026 revenue of approximately $352.2 million and earnings per share of $0.17, with the stock currently trading at $18.62 against an average analyst target of $21.64.

The primary focus for investors is the commercial trajectory of the gene therapy Elevidys following recent label restrictions that have limited its indicated use to ambulatory patients.

This quarterly report is considered a vital litmus test for the stability of the company's Duchenne muscular dystrophy franchise after a volatile year marked by clinical setbacks and declining sales. Markets are also looking for updates on the siRNA pipeline and regulatory milestones for legacy treatments to offset the current gene therapy headwinds.